The Department of Health is conducting a post-market review of the medicines listed on the Pharmaceutical Benefits Scheme (PBS) Opiate Dependence Treatment Program.
This is an opportunity to review the current program arrangements to ensure that Australians who have an opioid dependency continue to have access to medicines to help treat their opioid dependence. The Opiate Dependence Treatment Program (OTDP) Post-market Review (PMR) will examine important issues such as barriers to access and the future delivery of opioid dependence treatment. Medicines to be included in the ODTP PMR are buprenorphine (tablets and modified release injections), buprenorphine with naloxone (films) and methadone (oral liquid).
Public submissions to the ODTP PMR are now open and will close at 11.30pm AEST on Friday 1 October 2021. Further information on the ODTP PMR, including the process for providing a submission to the Review, is available on the PBS Reviews website.
The College will not be providing a formal submission, but encourages members to respond individually should they wish to do so.